Prudentia Sciences is an AI-powered technology company that accelerates investment in breakthrough therapies that change the world. Their platform empowers biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact. They also enable investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking. Additionally, Prudentia equips investors with data-driven insights to optimize capital allocation in drug asset transactions.

Prudentia's offerings include real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput. Their rapid AI-powered synthesis of dataroom into an asset assessment framework helps determine asset risks and value drivers. They provide AI-guided product profiles and asset valuations to guide portfolio strategy and decision-making, along with a concise and prioritized review of risks and opportunities for drug asset staging for emerging biotech and pharma. The platform integrates human expertise and advanced security measures, supporting large teams and workflows at scale.